Literature DB >> 3490481

Isolation and characterization of a collagen binding domain in human von Willebrand factor.

F I Pareti, Y Fujimura, J A Dent, L Z Holland, T S Zimmerman, Z M Ruggeri.   

Abstract

von Willebrand factor binds to fibrillar type I collagen in a rapid, temperature-independent, reversible, specific, and saturable manner. Evaluation of binding isotherms by Scatchard-type analysis demonstrated that 6-18 micrograms of von Willebrand factor bind per mg of collagen, with Ka between 2 and 8 X 10(8) M-1. Five distinct tryptic fragments, purified under denaturing and reducing conditions and representing over 75% of the molecular mass of the von Willebrand factor subunit, were tested for their capacity to inhibit the von Willebrand factor-collagen interaction. Complete inhibition was obtained with a 52/48-kDa fragment at a concentration of approximately 1 microM. The location of this fragment in the subunit was established to be between Val-449 and Lys-728. Fifteen monoclonal antibodies against the 52/48-kDa fragment inhibited von Willebrand factor binding to collagen. Six antibodies against other portions of the von Willebrand factor subunit had no inhibitory effect. The tryptic fragment was a competitive inhibitor of von Willebrand factor binding to collagen and, therefore, recognizes the same interaction site as the intact molecule. These studies precisely define a domain in the von Willebrand factor subunit that interacts with type I collagen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490481

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Genome sequence of the probiotic strain Bifidobacterium animalis subsp. lactis CNCM I-2494.

Authors:  Christian Chervaux; Christine Grimaldi; Alexander Bolotin; Benoit Quinquis; Sophie Legrain-Raspaud; Johan E T van Hylckama Vlieg; Gerard Denariaz; Tamara Smokvina
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

2.  The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.

Authors:  K A Cooney; W C Nichols; M E Bruck; W F Bahou; A D Shapiro; E J Bowie; H R Gralnick; D Ginsburg
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

3.  Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.

Authors:  K A Cooney; S E Lyons; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Intraglomerular deposition of fibrin/fibrinogen-related antigen in children with various renal diseases.

Authors:  H Kamitsuji; S Sakamoto; T Matsunaga; K Taira; S Kawahara; M Nakajima
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

5.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.

Authors:  Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells.

Authors:  T A Brock; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

7.  O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

Authors:  J A Carew; S M Quinn; J H Stoddart; D C Lynch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

8.  Sequence analysis of alpha 1(VI) and alpha 2(VI) chains of human type VI collagen reveals internal triplication of globular domains similar to the A domains of von Willebrand factor and two alpha 2(VI) chain variants that differ in the carboxy terminus.

Authors:  M L Chu; T C Pan; D Conway; H J Kuo; R W Glanville; R Timpl; K Mann; R Deutzmann
Journal:  EMBO J       Date:  1989-07       Impact factor: 11.598

9.  A new, rapid and reproducible method to obtain high quality endothelium in vitro.

Authors:  Nuria Jiménez; Vincent J D Krouwer; Jan A Post
Journal:  Cytotechnology       Date:  2012-05-10       Impact factor: 2.058

10.  Newer agents in antiplatelet therapy: a review.

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  J Blood Med       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.